Zedira Transglutaminase Services

Based on our profound expertise in transglutaminase, celiac disease and related fields, Zedira supports your R&D-work on a fee-for-service base.

Service categories include, but are not limited to:

  • Determination of microbial transglutaminase activity in food-preparations
  • Determination of gluten / gliadin content in food and food preparations
  • Production of transglutaminases from animal species (if not already listed in our product catalogue)
  • Modification of transglutaminases (biotin, fluorescent labels, …)
  • Development of transglutaminase assays for customer specific applications
  • Determination of human and animal transglutaminase inhibition in drug development
  • Organic synthesis of small transglutaminase related molecules (e.g. substrates, inhibitors).

Whatever you need - a product or a service around transglutaminase or related fields, please do not hesitate to contact us.

Phone: +49 6151 3251-00
E-mail: contact@zedira.com

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • BIO-Europe

    06.11.2017 - 08.11.2017
    Berlin, Germany

  • MEDICA

    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland